The increase in the population affected by non-alcoholic steatohepatitis (NASH) around the world is one of the main factors anticipated to boost the growth of the worldwide NASH therapies and diagnostics market over the predicted period. The increase in the number of obese and diabetic people worldwide is another reason boosting the non-alcoholic steatohepatitis (NASH) therapies and diagnostics market. For instance, it is typical for people to have both NASH and diabetes, and those who have both illnesses are at an increased risk of both liver- and non-liver-related illness as well as early death. The triple obesity epidemic and NASH are intimately related. The global non-alcoholic steatohepatitis (NASH) therapies and diagnostics market is likely to have considerable growth potential due to the rise in demand for safe and effective NASH medicines and diagnostics. Favorable government and non-government initiatives are anticipated to present companies in the global non-alcoholic steatohepatitis (NASH) treatments and diagnostics market with profitable growth prospects.
According to Coherent Market Insights, The market for therapies and diagnostics for Non-alcoholic Steatohepatitis (NASH) was estimated to be worth US$ 14,624.2 Mn in 2022 and is anticipated to grow to US$ 63,354.6 Mn by 2030 at a CAGR of 20.13% between 2023 and 2030.
Market Players in the Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Industry:
1. Novartis AG,
Cambridge, Massachusetts and Basel, Switzerland are home to Novartis AG, which was founded in March 1996. Novartis offers coverage for all types of medications, including those used for vaccinations, tests, eyeglasses, and veterinary care. This includes prescription and over-the-counter medications. Handling, marketing, operations, and research are a few of the duties that Novartis directly does through its businesses.
2. Merck & Co., Inc.,
The business was founded in 1668, and Rahway, New Jersey serves as its corporate headquarters. Pharmaceuticals, vaccines, biologic therapies, and goods for animal health are all produced by Merck. The company announced in September 2022 that it will acquire the cattle management company Vence for an undisclosed sum and merge it with Merck Animal Health. Merck Animal Health acquired PrognostiX Poultry in February 2021.
3. Gilead Sciences Inc.,
The business was established in 1987 and is based in Foster City, California, United States. The company's primary focus is on the development of antiviral medications for the treatment of COVID-19, hepatitis B, hepatitis C, flu, and HIV/AIDS. The company finished acquiring Tmunity Therapeutics through Kite Pharma in February 2023. In September 2020, Gilead declared it has struck an agreement to buy Immunomedics for $21 billion ($88 per share), obtaining control of the cancer therapy Trodelvy.
4. Allergan Plc
The firm was established in 2013 and has its headquarters in Dublin, Ireland. In the fields of medical aesthetics, eye care, gastroenterology, and the central nervous system, the company purchases, develops, produces, and promotes name-brand medications and medical devices. The purchase of Allergan by AbbVie was finalised on May 8, 2020.
5. Viking Therapeutics
The business was established in 2012 and is located in California, United States. A biopharmaceutical business is operated by Viking Therapeutics, Inc. The company's main area of interest is the creation of treatments for patients with metabolic and endocrine problems.
6. Novo Nordisk A/S,
The corporation, founded in 1923, has its headquarters in Bagsvaerd, Denmark. Novo Nordisk produces and sells pharmaceutical goods and services, including drugs and equipment for treating diabetes. Novo declared in November 2021 that it will pay $3.3 billion to buy Dicerna Pharmaceuticals and its RNAi therapies. In November 2020, the business announced it would purchase Emisphere Technologies for $1.8 billion,
7. Zydus Cadila
The firm was established in 1952 and is located in Ahmedabad. Zydus Lifesciences Limited is a business that deals with life sciences. The business produces and sells a variety of healthcare products, including formulations, vaccines, cosmeceuticals, diagnostics, diet and health foods, and active pharmaceutical components. The USFDA authorised Zydus Cadila's medication Desidustat to begin clinical trials on cancer patients in 2020. Cadila Healthcare Ltd. changes its name to Zydus Lifesciences Ltd. in 2022.
*Definition: Non-alcoholic steatohepatitis (NASH) is liver inflammation brought on by the presence of too many fat cells (fatty liver disease). It is brought on when that additional fat causes inflammation (liver swelling) and fibrosis (liver scarring).
